This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Pat Phillips
JAMA Contributor

JAMA. 1998;279:1936-1937.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

FOR 2 WEEKS leading up to the annual meeting of the American Society of Clinical Oncology (ASCO) last month, the media hoopla was intense surrounding 2 antiangiogenesis agents—compounds that inhibit the formation of new blood vessels, such as those that supply a cancerous tumor—that have shown potent anticancer activity in mice.

The frenzy of coverage in the nation's major newspapers, national news magazines, television, radio, and on the Internet led thousands of patients to besiege their physicians to help them obtain what some perceived as a cure for cancer.

It all started with a New York Times page 1 article on May 3 by medical reporter Gina Kolata that focused on research by Judah Folkman, MD, of Children's Hospital in Boston, Mass. "Within a year, if all goes well, the first cancer patient will be injected with 2 new drugs that can eradicate any type of cancer, with . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
Thomas et al.
JCO 2003;21:223-231.
ABSTRACT | FULL TEXT  

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin
Ryan et al.
The Oncologist 2002;7:58-65.
ABSTRACT | FULL TEXT  

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin
Ryan et al.
The Oncologist 1999;4:501-508.
ABSTRACT | FULL TEXT